ArticleScientific reports2026
An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR-ERBB2 heterodimerization.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Advanced prostate cancer remains challenging, driven in part by Epidermal Growth Factor (EGF) signaling that promotes migration, invasion, and angiogenesis. We evaluated LA3IK (LAIAVK), a novel MIEN1-based hexapeptide, for its ability to inhibit EGF-mediated tumor progression in androgen-independent, EGFR-overexpressing PC3 prostate cancer cells. Our full assessment included mechanistic studies of receptor dimerization, downstream signaling pathways, and functional assays for cancer cell behaviors. The results show that LA3IK selectively disrupts EGFR–ERBB2 heterodimerization, reducing phosphorylation of EGFR at Y1068 and downstream signaling through NF-κB, Src, and STAT3. This leads to impaired EGF-driven migration and invasion while sparing proliferation. Mechanistically, LA3IK induces a tryptophan blue shift in EGF and inhibits EGFR–ERBB2 interaction. Transcriptomic analyses revealed downregulation of angiogenesis-related genes ANGPTL4 and VEGFC. Crucially, LA3IK exhibited cancer-specificity, inhibiting EGF signaling in prostate tumors while preserving physiological EGFR function in healthy liver tissues. This tissue-specific action underscores LA3IK’s favorable safety profile. We therefore report LA3IK as the shortest peptide to date that effectively inhibits EGF-mediated tumorigenesis in advanced prostate cancer with minimal off-target effects, highlighting its potential as a precise therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.